Eli Lilly’s migraine prevention drug Emgality not superior to Pfizer’s Nurtec ODT in head-to-head
In a head-to-head clinical trial, Eli Lilly’s injectable migraine drug Emgality was not superior to the Nurtec ODT tablets out of Pfizer on a primary measure of percent of patients reaching 50% or better reduction in monthly migraine headache days.
The response rates were similar, Lilly said in a Friday afternoon press release. The Indianapolis Big Pharma said its monoclonal antibody, first approved in the fall of 2018, was “numerically better” than Nurtec ODT on “key secondary endpoints.” Lilly did not disclose any more data and said it will present full results later this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
